Company Overview of Jennerex Biotherapeutics, Inc.
Jennerex Biotherapeutics, Inc. develops oncolytic products for cancer. Its pipeline includes JX-594 for treating patients with liver and colorectal cancer; JX-929 for treating patients with pancreatic cancer; JX-1395 for treating patients with prostate cancer; and JX-next generation therapeutic classes for treating patients with various other cancers. The company’s products are designed to attack cancer tumors through synergistic and complementary mechanisms of action, such as lysis of cancer cells through viral replication, reduction of the blood supply to tumors through vascular targeting and destruction, and stimulation of the body's immune response against cancer cells. Jennerex Biothera...
450 Sansome Street
San Francisco, CA 94111
Founded in 2003
Key Executives for Jennerex Biotherapeutics, Inc.
Chief Executive Officer, President and Director
Founder, Chief Medical Officer, President of Research & Development and Director
Executive Vice President of Corporate Strategy
Head of Pusan Research Site and Research Advisor
Compensation as of Fiscal Year 2015.
Jennerex Biotherapeutics, Inc. Key Developments
Jennerex Biotherapeutics, Inc. Presents at BIO International Convention, Jun-23-2014
Jun 17 14
Jennerex Biotherapeutics, Inc. Presents at BIO International Convention, Jun-23-2014 . Venue: San Diego Convention Center, San Diego, California, United States.
Jennerex Biotherapeutics, Inc. Presents at 12th Annual BIO Investor Forum, Oct-08-2013
Sep 25 13
Jennerex Biotherapeutics, Inc. Presents at 12th Annual BIO Investor Forum, Oct-08-2013 . Venue: The Palace Hotel, 2 New Montgomery Street, San Francisco, CA 94105, United States. Speakers: Laurent Fischer, Chief Executive Officer, President and Director.
Jennerex Biotherapeutics, Inc. Announces Phase 2 Study of Pexa-Vec in Second-Line Advanced Liver Cancer Did Not Meet its Primary Endpoint
Sep 3 13
Jennerex Biotherapeutics, Inc. announced that TRAVERSE, a randomized Phase 2b study of Pexa-Vec in second-line, advanced liver cancer patients had reached the pre-specified number of events for analysis. The study failed to meet its primary endpoint of overall survival for Pexa-Vec plus best supportive care (BSC) compared to BSC. Pexa-Vec was generally well tolerated with an adverse event profile consistent with previous Pexa-Vec studies in patients with advanced liver cancer. Additional analyses will be conducted to further understand these data. Pexa-Vec is also being investigated in Phase 2 studies in colorectal, kidney and ovarian cancer. Jennerex will continue to advance the Pexa-Vec program in these indications while evaluating the Pexa-Vec liver cancer program. The Jennerex pipeline also includes JX-929, an oncolytic immunotherapy in Phase 1 clinical trials, and a platform for novel oncolytic and antibody-based immunotherapies.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|